FTC Examination of Pharmacy Benefit Managers and Drug Price Inflation

Thursday, 11 July 2024, 14:01

The Federal Trade Commission is scrutinizing the actions of pharmacy benefit managers (PBMs) amidst concerns that they are responsible for inflating prescription drug prices. PBMs are accused of artificially driving up costs, raising questions about their practices and impact on the pharmaceutical industry. The investigation highlights the need for transparency and oversight in the pricing strategies of PBMs to ensure fair access to affordable medications.

Marketplace — FTC Examination of Pharmacy Benefit Managers and Drug Price Inflation

FTC Investigation on Pharmacy Benefit Managers

The Federal Trade Commission (FTC) is examining the role of pharmacy benefit managers (PBMs) in the pharmaceutical market.

Artificial Inflation of Drug Prices

Accusations suggest that PBMs are artificially driving up prescription drug prices through their practices.

Transparency Needed: There are concerns regarding the lack of transparency in PBM pricing strategies.
Impact on Industry: The investigation sheds light on the potential impact of PBMs on drug affordability.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.

FTC Investigation on Pharmacy Benefit Managers

Artificial Inflation of Drug Prices

Related posts